Company Description
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.
The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 26, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Richard Kender |
Contact Details
Address: 101 Cambridgepark Drive Cambridge, Massachusetts 02140 United States | |
| Phone | 617 945 9626 |
| Website | serestherapeutics.com |
Stock Details
| Ticker Symbol | MCRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001609809 |
| CUSIP Number | 81750R201 |
| ISIN Number | US81750R2013 |
| Employer ID | 27-4326290 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard N. Kender B.S., M.B.A. | Interim Chief Executive Officer and Executive Chair |
| Thomas J. DesRosier Esq., J.D. | Executive Vice President and Chief Legal Officer |
| Dr. Matthew R. Henn Ph.D. | President and Chief Scientific Officer |
| Marella Thorell C.P.A. | Executive Vice President and Chief Financial Officer |
| Kelly Brady M.S. | Executive Vice President and Chief Operating Officer |
| Chris McChalicher | Executive Vice President and Chief Technology Officer |
| Dr. Teresa L. Young Ph.D., R.Ph. | Executive Vice President and Chief Commercial and Strategy Officer |
| Dr. Dennis M. Walling M.D. | Senior Vice President of Clinical Development and Head of Clinical Research |
| Ann Kurowski | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2026 | 144 | Filing |
| Mar 16, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 3, 2025 | 8-K | Current Report |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 10-Q | Quarterly Report |